These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28181117)

  • 1. CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
    Luzum JA; Sweet KM; Binkley PF; Schmidlen TJ; Jarvis JP; Christman MF; Sadee W; Kitzmiller JP
    Pharm Res; 2017 Aug; 34(8):1615-1625. PubMed ID: 28181117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
    Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
    Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
    Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
    J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
    Metra M; Torp-Pedersen C; Swedberg K; Cleland JG; Di Lenarda A; Komajda M; Remme WJ; Lutiger B; Scherhag A; Lukas MA; Charlesworth A; Poole-Wilson PA
    Eur Heart J; 2005 Nov; 26(21):2259-68. PubMed ID: 16040619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
    Ingram A; Valente M
    J Pharm Pract; 2020 Feb; 33(1):96-98. PubMed ID: 29916290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
    Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Petersen HH; Torp-Pedersen C; Riahi S; Jøns C
    Europace; 2018 Feb; 20(2):301-307. PubMed ID: 28339659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
    Fröhlich H; Zhao J; Täger T; Cebola R; Schellberg D; Katus HA; Grundtvig M; Hole T; Atar D; Agewall S; Frankenstein L
    Circ Heart Fail; 2015 Sep; 8(5):887-96. PubMed ID: 26175538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure.
    Rector TS; Anand IS; Nelson DB; Ensrud KE
    J Am Geriatr Soc; 2008 Jun; 56(6):1021-7. PubMed ID: 18384583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
    Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL; Talbert RL
    J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing beta-blocking effects of carvedilol and metoprolol.
    Stoschitzky K; Koshucharova G; Zweiker R; Maier R; Watzinger N; Fruhwald FM; Klein W
    Eur J Heart Fail; 2001 Jun; 3(3):343-9. PubMed ID: 11378006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
    Vardeny O; Detry MA; Moran JJ; Johnson MR; Sweitzer NK
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):500-6. PubMed ID: 19034036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
    Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
    Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
    Lymperopoulos A; McCrink KA; Brill A
    Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
    Azevedo ER; Kubo T; Mak S; Al-Hesayen A; Schofield A; Allan R; Kelly S; Newton GE; Floras JS; Parker JD
    Circulation; 2001 Oct; 104(18):2194-9. PubMed ID: 11684630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
    Piccirillo G; Quaglione R; Nocco M; Naso C; Moisè A; Lionetti M; Di Carlo S; Marigliano V
    Am J Cardiol; 2002 Nov; 90(10):1113-7. PubMed ID: 12423713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.